O	O	O	0	14	Glucocorticoid	Glucocorticoid	B-NP	NN	O	14	NMOD	O
O	O	O	14	15	-	-	B-PP	HYPH	O	14	P	O
O	O	O	15	23	mediated	mediate	B-NP	VBN	O	4	NMOD	O
O	O	O	24	34	repression	repression	I-NP	NN	O	14	NMOD	O
O	O	O	35	37	of	of	B-PP	IN	O	4	NMOD	O
T12	B-Entity	B-Entity	38	46	cytokine	cytokine	B-NP	NN	B-DNA	8	NMOD	B-DNA
T12	I-Entity	I-Entity	47	51	gene	gene	I-NP	NN	I-DNA	8	NMOD	I-DNA
O	O	O	52	65	transcription	transcription	I-NP	NN	O	5	PMOD	O
O	O	O	66	68	in	in	B-PP	IN	O	4	NMOD	O
O	O	O	69	74	human	human	B-NP	JJ	O	11	NMOD	O
O	O	O	75	84	arteritis	arteritis	I-NP	NN	O	9	PMOD	O
O	O	O	84	85	-	-	B-NP	HYPH	O	14	P	O
O	O	O	85	89	SCID	SCID	I-NP	NN	B-protein	14	NMOD	B-protein
O	O	O	90	98	chimeras	chimera	I-NP	NNS	I-protein	0	ROOT	I-protein
O	O	O	98	99	.	.	O	.	O	14	P	O

O	O	O	101	106	Giant	Giant	B-NP	JJ	O	3	NMOD	O
O	O	O	107	111	cell	cell	I-NP	NN	O	3	NMOD	O
O	O	O	112	121	arteritis	arteritis	I-NP	NN	O	7	SUB	O
O	O	O	122	123	(	(	O	(	O	6	DEP	O
O	O	O	123	126	GCA	GCA	B-NP	NN	B-protein	6	DEP	B-protein
O	O	O	126	127	)	)	O	)	O	3	NMOD	O
O	O	O	128	130	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	131	132	a	a	B-NP	DT	O	10	NMOD	O
O	O	O	133	143	vasculitic	vasculitic	I-NP	JJ	O	10	NMOD	O
O	O	O	144	152	syndrome	syndrome	I-NP	NN	O	7	PRD	O
O	O	O	153	157	that	that	B-NP	WDT	O	10	NMOD	O
O	O	O	158	172	preferentially	preferentially	B-ADVP	RB	O	13	VMOD	O
O	O	O	173	180	affects	affect	B-VP	VBZ	O	11	SBAR	O
O	O	O	181	187	medium	medium	B-NP	NN	O	19	NMOD	O
O	O	O	188	191	and	and	I-NP	CC	O	19	NMOD	O
O	O	O	192	197	large	large	I-NP	JJ	O	19	NMOD	O
O	O	O	197	198	-	-	I-NP	HYPH	O	19	NMOD	O
O	O	O	198	203	sized	size	I-NP	VBN	O	19	NMOD	O
O	O	O	204	212	arteries	artery	I-NP	NNS	O	13	OBJ	O
O	O	O	212	213	.	.	O	.	O	7	P	O

O	O	O	214	228	Glucocorticoid	Glucocorticoid	B-NP	NN	O	2	NMOD	O
O	O	O	229	236	therapy	therapy	I-NP	NN	O	3	SUB	O
O	O	O	237	245	resolves	resolve	B-VP	VBZ	O	13	VMOD	O
O	O	O	246	254	clinical	clinical	B-NP	JJ	O	5	NMOD	O
O	O	O	255	263	symptoms	symptom	I-NP	NNS	O	3	OBJ	O
O	O	O	264	270	within	within	B-PP	IN	O	3	VMOD	O
O	O	O	271	276	hours	hour	B-NP	NNS	O	6	PMOD	O
O	O	O	277	279	to	to	B-PP	TO	O	7	NMOD	O
O	O	O	280	284	days	day	B-NP	NNS	O	8	PMOD	O
O	O	O	284	285	,	,	O	,	O	13	P	O
O	O	O	286	289	but	but	O	CC	O	13	VMOD	O
O	O	O	290	297	therapy	therapy	B-NP	NN	O	13	SUB	O
O	O	O	298	301	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	302	304	to	to	I-VP	TO	O	15	VMOD	O
O	O	O	305	307	be	be	I-VP	VB	O	13	VMOD	O
O	O	O	308	317	continued	continue	I-VP	VBN	O	15	VC	O
O	O	O	318	322	over	over	B-PP	IN	O	16	VMOD	O
O	O	O	323	330	several	several	B-NP	JJ	O	19	NMOD	O
O	O	O	331	336	years	year	I-NP	NNS	O	17	PMOD	O
O	O	O	337	339	to	to	B-VP	TO	O	21	VMOD	O
O	O	O	340	347	prevent	prevent	I-VP	VB	O	13	VMOD	O
O	O	O	348	355	disease	disease	B-NP	NN	O	23	NMOD	O
O	O	O	356	364	relapses	relapse	I-NP	NNS	O	21	OBJ	O
O	O	O	364	365	.	.	O	.	O	13	P	O

O	O	O	366	368	It	It	B-NP	PRP	O	2	SUB	O
O	O	O	369	371	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	372	375	not	not	I-VP	RB	O	2	VMOD	O
O	O	O	376	381	known	know	I-VP	VBN	O	2	VC	O
O	O	O	382	389	whether	whether	B-SBAR	IN	O	9	DEP	O
O	O	O	390	393	and	and	O	CC	O	9	DEP	O
O	O	O	394	397	how	how	B-ADVP	WRB	O	9	DEP	O
O	O	O	398	413	glucocorticoids	glucocorticoid	B-NP	NNS	O	9	SUB	O
O	O	O	414	420	affect	affect	B-VP	VBP	O	17	DEP	O
O	O	O	421	424	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	425	433	function	function	I-NP	NN	O	9	OBJ	O
O	O	O	434	436	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	437	440	the	the	B-NP	DT	O	15	NMOD	O
O	O	O	441	453	inflammatory	inflammatory	I-NP	JJ	O	15	NMOD	O
O	O	O	454	464	infiltrate	infiltrate	I-NP	NN	O	12	PMOD	O
O	O	O	465	467	or	or	O	CC	O	17	DEP	O
O	O	O	468	471	why	why	B-ADVP	WRB	O	4	VMOD	O
O	O	O	472	475	the	the	B-NP	DT	O	19	NMOD	O
O	O	O	476	483	disease	disease	I-NP	NN	O	20	SUB	O
O	O	O	484	492	persists	persist	B-VP	VBZ	O	17	AMOD	O
O	O	O	493	506	subclinically	subclinically	B-ADVP	RB	O	20	VMOD	O
O	O	O	507	514	despite	despite	B-PP	IN	O	20	VMOD	O
O	O	O	515	522	chronic	chronic	B-NP	JJ	O	24	NMOD	O
O	O	O	523	532	treatment	treatment	I-NP	NN	O	22	PMOD	O
O	O	O	532	533	.	.	O	.	O	2	P	O

O	O	O	534	537	GCA	GCA	B-NP	NN	B-protein	2	SUB	B-protein
O	O	O	538	540	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	541	545	self	self	B-ADJP	AFX	O	2	PRD	O
O	O	O	545	546	-	-	O	HYPH	O	3	P	O
O	O	O	546	555	sustained	sustain	B-VP	VBN	O	3	DEP	O
O	O	O	556	558	in	in	B-PP	IN	O	5	VMOD	O
O	O	O	559	567	temporal	temporal	B-NP	JJ	O	8	NMOD	O
O	O	O	568	576	arteries	artery	I-NP	NNS	O	6	PMOD	O
O	O	O	577	586	engrafted	engraft	B-VP	VBN	O	8	NMOD	O
O	O	O	587	591	into	into	B-PP	IN	O	9	VMOD	O
O	O	O	592	596	SCID	SCID	B-NP	NN	O	12	NMOD	O
O	O	O	597	601	mice	mouse	I-NP	NNS	O	10	PMOD	O
O	O	O	601	602	,	,	O	,	O	2	P	O
O	O	O	603	612	providing	provide	B-VP	VBG	O	2	VMOD	O
O	O	O	613	614	a	a	B-NP	DT	O	16	NMOD	O
O	O	O	615	620	model	model	I-NP	NN	O	14	OBJ	O
O	O	O	621	623	in	in	B-PP	IN	O	16	NMOD	O
O	O	O	624	629	which	which	B-NP	WDT	O	17	PMOD	O
O	O	O	630	633	the	the	B-NP	DT	O	20	NMOD	O
O	O	O	634	644	mechanisms	mechanism	I-NP	NNS	O	28	SUB	O
O	O	O	645	647	of	of	B-PP	IN	O	20	NMOD	O
O	O	O	648	654	action	action	B-NP	NN	O	24	NMOD	O
O	O	O	655	658	and	and	I-NP	CC	O	24	NMOD	O
O	O	O	659	670	limitations	limitation	I-NP	NNS	O	21	PMOD	O
O	O	O	671	673	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	674	688	glucocorticoid	glucocorticoid	B-NP	NN	O	27	NMOD	O
O	O	O	689	696	therapy	therapy	I-NP	NN	O	25	PMOD	O
O	O	O	697	700	can	can	B-VP	MD	O	17	SBAR	O
O	O	O	701	703	be	be	I-VP	VB	O	28	VC	O
O	O	O	704	712	examined	examine	I-VP	VBN	O	29	VC	O
O	O	O	713	715	in	in	B-ADVP	FW	O	30	VMOD	O
O	O	O	716	720	vivo	vivo	I-ADVP	FW	O	31	AMOD	O
O	O	O	720	721	.	.	O	.	O	2	P	O

O	O	O	722	736	Administration	Administration	B-NP	NN	O	13	SUB	O
O	O	O	737	739	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	740	753	dexamethasone	dexamethasone	B-NP	NN	O	2	PMOD	O
O	O	O	754	756	to	to	B-PP	TO	O	1	NMOD	O
O	O	O	757	765	temporal	temporal	B-NP	JJ	O	9	NMOD	O
O	O	O	766	772	artery	artery	I-NP	NN	O	9	NMOD	O
O	O	O	772	773	-	-	B-NP	HYPH	O	9	NMOD	O
O	O	O	773	777	SCID	SCID	I-NP	NN	B-protein	9	NMOD	B-protein
O	O	O	778	786	chimeras	chimera	I-NP	NNS	I-protein	4	PMOD	I-protein
O	O	O	787	790	for	for	B-PP	IN	O	1	NMOD	O
O	O	O	791	792	1	1	B-NP	CD	O	12	NMOD	O
O	O	O	793	795	wk	wk	I-NP	NN	O	10	PMOD	O
O	O	O	796	803	induced	induce	B-VP	VBD	O	0	ROOT	O
O	O	O	804	805	a	a	B-NP	DT	O	16	NMOD	O
O	O	O	806	813	partial	partial	I-NP	JJ	O	16	NMOD	O
O	O	O	814	825	suppression	suppression	I-NP	NN	O	13	OBJ	O
O	O	O	826	828	of	of	B-PP	IN	O	16	NMOD	O
O	O	O	829	830	T	T	B-NP	NN	B-cell_type	19	NMOD	B-cell_type
O	O	O	831	835	cell	cell	I-NP	NN	I-cell_type	22	NMOD	I-cell_type
O	O	O	836	839	and	and	I-NP	CC	O	22	NMOD	O
O	O	O	840	850	macrophage	macrophage	I-NP	NN	O	22	NMOD	O
O	O	O	851	859	function	function	I-NP	NN	O	17	PMOD	O
O	O	O	860	862	as	as	B-SBAR	IN	O	13	VMOD	O
O	O	O	863	872	indicated	indicate	B-VP	VBN	O	23	SBAR	O
O	O	O	873	875	by	by	B-PP	IN	O	24	VMOD	O
O	O	O	876	879	the	the	B-NP	DT	O	29	NMOD	O
O	O	O	880	887	reduced	reduce	I-NP	VBN	O	29	NMOD	O
O	O	O	888	894	tissue	tissue	I-NP	NN	O	29	NMOD	O
O	O	O	895	909	concentrations	concentration	I-NP	NNS	O	25	PMOD	O
O	O	O	910	912	of	of	B-PP	IN	O	29	NMOD	O
T1	B-Protein	B-Protein	913	915	IL	IL	B-NP	NN	B-protein	43	NMOD	B-protein
T1	I-Protein	I-Protein	915	916	-	-	B-NP	HYPH	I-protein	31	NMOD	I-protein
T1	I-Protein	I-Protein	916	917	2	2	I-NP	CD	I-protein	31	NMOD	I-protein
O	O	O	917	918	,	,	O	,	O	43	P	O
T2	B-Protein	B-Protein	919	921	IL	IL	B-NP	NN	B-protein	37	NMOD	B-protein
T2	I-Protein	I-Protein	921	922	-	-	B-NP	HYPH	I-protein	37	NMOD	I-protein
T2	I-Protein	I-Protein	922	927	1beta	1beta	I-NP	NN	I-protein	43	NMOD	I-protein
O	O	O	927	928	,	,	O	,	O	43	P	O
O	O	O	929	932	and	and	O	CC	O	43	NMOD	O
T3	B-Protein	B-Protein	933	935	IL	IL	B-NP	NN	B-RNA	43	NMOD	B-RNA
T3	I-Protein	I-Protein	935	936	-	-	O	HYPH	I-RNA	43	NMOD	I-RNA
T3	I-Protein	I-Protein	936	937	6	6	B-NP	CD	I-RNA	43	NMOD	I-RNA
O	O	O	938	942	mRNA	mRNA	I-NP	NN	I-RNA	30	PMOD	I-RNA
O	O	O	942	943	,	,	O	,	O	23	P	O
O	O	O	944	947	and	and	O	CC	O	23	PMOD	O
O	O	O	948	950	by	by	B-PP	IN	O	23	DEP	O
O	O	O	951	954	the	the	B-NP	DT	O	49	NMOD	O
O	O	O	955	965	diminished	diminish	I-NP	VBN	O	49	NMOD	O
O	O	O	966	976	expression	expression	I-NP	NN	O	46	PMOD	O
O	O	O	977	979	of	of	B-PP	IN	O	49	NMOD	O
O	O	O	980	989	inducible	inducible	B-NP	JJ	O	50	PMOD	O
O	O	O	990	992	NO	NO	I-NP	NN	B-protein	53	NMOD	B-protein
O	O	O	993	1001	synthase	synthase	I-NP	NN	I-protein	51	NMOD	I-protein
O	O	O	1001	1002	.	.	O	.	O	13	P	O

O	O	O	1003	1005	In	In	B-PP	IN	O	10	VMOD	O
O	O	O	1006	1014	contrast	contrast	B-NP	NN	O	1	PMOD	O
O	O	O	1014	1015	,	,	O	,	O	10	P	O
O	O	O	1016	1025	synthesis	synthesis	B-NP	NN	O	10	SUB	O
O	O	O	1026	1028	of	of	B-PP	IN	O	4	NMOD	O
T4	B-Protein	B-Protein	1029	1032	IFN	IFN	B-NP	NN	B-RNA	9	NMOD	B-RNA
T4	I-Protein	I-Protein	1032	1033	-	-	B-NP	HYPH	I-RNA	9	NMOD	I-RNA
T4	I-Protein	I-Protein	1033	1038	gamma	gamma	I-NP	NN	I-RNA	9	NMOD	I-RNA
O	O	O	1039	1043	mRNA	mRNA	I-NP	NN	I-RNA	5	PMOD	I-RNA
O	O	O	1044	1047	was	be	B-VP	VBD	O	21	VMOD	O
O	O	O	1048	1052	only	only	I-VP	RB	O	10	VMOD	O
O	O	O	1053	1061	slightly	slightly	I-VP	RB	O	11	AMOD	O
O	O	O	1062	1071	decreased	decrease	I-ADJP	VBN	O	10	VC	O
O	O	O	1071	1072	,	,	O	,	O	16	P	O
O	O	O	1073	1076	and	and	O	CC	O	16	NMOD	O
O	O	O	1077	1087	expression	expression	B-NP	NN	O	21	SUB	O
O	O	O	1088	1090	of	of	B-PP	IN	O	16	NMOD	O
T5	B-Protein	B-Protein	1091	1094	TGF	TGF	B-NP	NN	B-protein	20	NMOD	B-protein
T5	I-Protein	I-Protein	1094	1095	-	-	B-NP	HYPH	I-protein	20	NMOD	I-protein
T5	I-Protein	I-Protein	1095	1100	beta1	beta1	I-NP	NN	I-protein	17	PMOD	I-protein
O	O	O	1101	1104	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1105	1115	unaffected	unaffected	B-ADJP	JJ	O	21	PRD	O
O	O	O	1115	1116	.	.	O	.	O	21	P	O

O	O	O	1117	1122	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	1123	1131	findings	finding	I-NP	NNS	O	3	SUB	O
O	O	O	1132	1142	correlated	correlate	B-VP	VBD	O	0	ROOT	O
O	O	O	1143	1147	with	with	B-PP	IN	O	3	VMOD	O
O	O	O	1148	1158	activation	activation	B-NP	NN	O	11	NMOD	O
O	O	O	1159	1161	of	of	B-PP	IN	O	5	NMOD	O
O	O	O	1162	1165	the	the	B-NP	DT	O	9	NMOD	O
T6	B-Protein	B-Protein	1166	1178	IkappaBalpha	IkappaBalpha	I-NP	NN	B-DNA	9	NMOD	B-DNA
O	O	O	1179	1183	gene	gene	I-NP	NN	I-DNA	6	PMOD	I-DNA
O	O	O	1184	1187	and	and	O	CC	O	11	NMOD	O
O	O	O	1188	1196	blockade	blockade	B-NP	NN	O	4	PMOD	O
O	O	O	1197	1199	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	1200	1203	the	the	B-NP	DT	O	15	NMOD	O
O	O	O	1204	1211	nuclear	nuclear	I-NP	JJ	O	15	NMOD	O
O	O	O	1212	1225	translocation	translocation	I-NP	NN	O	12	PMOD	O
O	O	O	1226	1228	of	of	B-PP	IN	O	15	NMOD	O
T13	B-Entity	B-Entity	1229	1237	NFkappaB	NFkappaB	B-NP	NN	B-protein	16	PMOD	B-protein
O	O	O	1238	1240	in	in	B-PP	IN	O	11	NMOD	O
O	O	O	1241	1244	the	the	B-NP	DT	O	21	NMOD	O
O	O	O	1245	1261	xenotransplanted	xenotransplante	I-NP	VBN	O	21	NMOD	O
O	O	O	1262	1268	tissue	tissue	I-NP	NN	O	18	PMOD	O
O	O	O	1268	1269	.	.	O	.	O	3	P	O

O	O	O	1270	1274	Dose	Dose	B-NP	NN	O	4	NMOD	O
O	O	O	1274	1275	-	-	I-NP	HYPH	O	4	NMOD	O
O	O	O	1275	1283	response	response	I-NP	NN	O	4	NMOD	O
O	O	O	1284	1295	experiments	experiment	I-NP	NNS	O	5	SUB	O
O	O	O	1296	1305	suggested	suggest	B-VP	VBD	O	0	ROOT	O
O	O	O	1306	1310	that	that	B-SBAR	IN	O	5	VMOD	O
O	O	O	1311	1318	steroid	steroid	B-NP	NN	O	8	NMOD	O
O	O	O	1319	1324	doses	dose	I-NP	NNS	O	14	SUB	O
O	O	O	1325	1334	currently	currently	B-VP	RB	O	10	VMOD	O
O	O	O	1335	1339	used	use	I-VP	VBN	O	8	NMOD	O
O	O	O	1340	1342	in	in	B-PP	IN	O	10	VMOD	O
O	O	O	1343	1351	clinical	clinical	B-NP	JJ	O	13	NMOD	O
O	O	O	1352	1360	medicine	medicine	I-NP	NN	O	11	PMOD	O
O	O	O	1361	1364	are	be	B-VP	VBP	O	6	SBAR	O
O	O	O	1365	1375	suboptimal	suboptimal	B-ADJP	JJ	O	14	PRD	O
O	O	O	1376	1378	in	in	B-PP	IN	O	15	AMOD	O
O	O	O	1379	1389	repressing	repress	B-VP	VBG	O	16	PMOD	O
T14	B-Entity	B-Entity	1390	1398	NFkappaB	NFkappaB	B-NP	NN	B-protein	22	NMOD	B-protein
O	O	O	1398	1399	-	-	O	HYPH	O	22	P	O
O	O	O	1399	1407	mediated	mediate	B-NP	VBN	O	22	NMOD	O
O	O	O	1408	1416	cytokine	cytokine	I-NP	NN	B-protein	22	NMOD	B-protein
O	O	O	1417	1427	production	production	I-NP	NN	O	17	OBJ	O
O	O	O	1428	1430	in	in	B-PP	IN	O	22	NMOD	O
O	O	O	1431	1434	the	the	B-NP	DT	O	26	NMOD	O
O	O	O	1435	1447	inflammatory	inflammatory	I-NP	JJ	O	26	NMOD	O
O	O	O	1448	1455	lesions	lesion	I-NP	NNS	O	23	PMOD	O
O	O	O	1455	1456	.	.	O	.	O	5	P	O

O	O	O	1457	1464	Chronic	Chronic	B-NP	JJ	O	3	NMOD	O
O	O	O	1465	1472	steroid	steroid	I-NP	NN	O	3	NMOD	O
O	O	O	1473	1480	therapy	therapy	I-NP	NN	O	4	SUB	O
O	O	O	1481	1484	was	be	B-VP	VBD	O	20	VMOD	O
O	O	O	1485	1489	able	able	B-ADJP	JJ	O	4	PRD	O
O	O	O	1490	1492	to	to	B-VP	TO	O	7	VMOD	O
O	O	O	1493	1500	deplete	deplete	I-VP	VB	O	5	AMOD	O
O	O	O	1501	1504	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	1505	1506	T	T	I-NP	NN	B-protein	11	NMOD	B-protein
O	O	O	1507	1511	cell	cell	I-NP	NN	I-protein	11	NMOD	I-protein
O	O	O	1512	1520	products	product	I-NP	NNS	I-protein	18	NMOD	I-protein
T7	B-Protein	B-Protein	1521	1523	IL	IL	I-NP	NN	B-protein	18	NMOD	B-protein
T7	I-Protein	I-Protein	1523	1524	-	-	B-NP	HYPH	I-protein	12	NMOD	I-protein
T7	I-Protein	I-Protein	1524	1525	2	2	I-NP	CD	I-protein	13	NMOD	I-protein
O	O	O	1526	1529	and	and	I-NP	CC	O	18	NMOD	O
T8	B-Protein	B-Protein	1530	1533	IFN	IFN	I-NP	NN	B-protein	18	NMOD	B-protein
T8	I-Protein	I-Protein	1533	1534	-	-	O	HYPH	I-protein	18	P	I-protein
T8	I-Protein	I-Protein	1534	1539	gamma	gamma	B-NP	SYM	I-protein	7	OBJ	I-protein
O	O	O	1539	1540	,	,	O	,	O	20	P	O
O	O	O	1541	1548	whereas	whereas	O	IN	O	0	ROOT	O
O	O	O	1549	1552	the	the	B-NP	DT	O	22	NMOD	O
O	O	O	1553	1563	activation	activation	I-NP	NN	O	28	SUB	O
O	O	O	1564	1566	of	of	B-PP	IN	O	22	NMOD	O
O	O	O	1567	1573	tissue	tissue	B-NP	NN	B-cell_type	27	NMOD	B-cell_type
O	O	O	1573	1574	-	-	O	HYPH	I-cell_type	24	P	I-cell_type
O	O	O	1574	1586	infiltrating	infiltrate	B-VP	VBG	I-cell_type	27	NMOD	I-cell_type
O	O	O	1587	1598	macrophages	macrophage	B-NP	NNS	I-cell_type	23	PMOD	I-cell_type
O	O	O	1599	1602	was	be	B-VP	VBD	O	20	VMOD	O
O	O	O	1603	1607	only	only	I-VP	RB	O	28	VMOD	O
O	O	O	1608	1617	partially	partially	I-VP	RB	O	29	AMOD	O
O	O	O	1618	1626	affected	affect	I-VP	VBN	O	28	VC	O
O	O	O	1626	1627	.	.	O	.	O	20	P	O

T9	B-Protein	B-Protein	1628	1630	IL	IL	B-NP	NN	B-protein	4	NMOD	B-protein
T9	I-Protein	I-Protein	1630	1631	-	-	I-NP	HYPH	I-protein	4	NMOD	I-protein
T9	I-Protein	I-Protein	1631	1636	1beta	1beta	I-NP	NN	I-protein	4	NMOD	I-protein
O	O	O	1637	1650	transcription	transcription	I-NP	NN	O	5	SUB	O
O	O	O	1651	1654	was	be	B-VP	VBD	O	16	VMOD	O
O	O	O	1655	1664	abrogated	abrogate	I-VP	VBN	O	5	VC	O
O	O	O	1664	1665	;	;	O	:	O	16	P	O
O	O	O	1666	1668	in	in	B-PP	IN	O	16	VMOD	O
O	O	O	1669	1677	contrast	contrast	B-NP	NN	O	8	PMOD	O
O	O	O	1677	1678	,	,	O	,	O	16	P	O
T10	B-Protein	B-Protein	1679	1682	TGF	TGF	B-NP	NN	B-protein	15	NMOD	B-protein
T10	I-Protein	I-Protein	1682	1683	-	-	B-NP	HYPH	O	15	NMOD	O
T10	I-Protein	I-Protein	1683	1688	beta1	beta1	I-NP	NN	B-RNA	14	NMOD	B-RNA
O	O	O	1689	1693	mRNA	mRNA	I-NP	NN	I-RNA	15	NMOD	I-RNA
O	O	O	1694	1703	synthesis	synthesis	I-NP	NN	O	16	SUB	O
O	O	O	1704	1707	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1708	1715	steroid	steroid	B-ADJP	NN	O	16	PRD	O
O	O	O	1716	1725	resistant	resistant	I-ADJP	JJ	O	17	AMOD	O
O	O	O	1725	1726	.	.	O	.	O	16	P	O

O	O	O	1727	1730	The	The	B-NP	DT	O	2	NMOD	O
O	O	O	1731	1742	persistence	persistence	I-NP	NN	O	18	SUB	O
O	O	O	1743	1745	of	of	B-PP	IN	O	2	NMOD	O
T11	B-Protein	B-Protein	1746	1749	TGF	TGF	B-NP	NN	B-protein	6	NMOD	B-protein
T11	I-Protein	I-Protein	1749	1750	-	-	B-NP	HYPH	I-protein	6	P	I-protein
T11	I-Protein	I-Protein	1750	1755	beta1	beta1	I-NP	NN	I-protein	3	PMOD	I-protein
O	O	O	1755	1756	-	-	O	HYPH	O	6	P	O
O	O	O	1756	1768	transcribing	transcribe	B-VP	VBG	O	6	NMOD	O
O	O	O	1769	1780	macrophages	macrophage	B-NP	NNS	B-cell_type	8	OBJ	B-cell_type
O	O	O	1780	1781	,	,	O	,	O	2	P	O
O	O	O	1782	1789	despite	despite	B-PP	IN	O	18	VMOD	O
O	O	O	1790	1799	paralysis	paralysis	B-NP	NN	O	11	PMOD	O
O	O	O	1800	1802	of	of	B-PP	IN	O	12	NMOD	O
O	O	O	1803	1804	T	T	B-NP	NN	B-cell_type	16	NMOD	B-cell_type
O	O	O	1805	1809	cell	cell	I-NP	NN	I-cell_type	16	NMOD	I-cell_type
O	O	O	1810	1818	function	function	I-NP	NN	O	13	PMOD	O
O	O	O	1818	1819	,	,	O	,	O	18	P	O
O	O	O	1820	1823	may	may	B-VP	MD	O	0	ROOT	O
O	O	O	1824	1831	provide	provide	I-VP	VB	O	18	VC	O
O	O	O	1832	1834	an	an	B-NP	DT	O	21	NMOD	O
O	O	O	1835	1846	explanation	explanation	I-NP	NN	O	19	OBJ	O
O	O	O	1847	1850	for	for	B-PP	IN	O	21	NMOD	O
O	O	O	1851	1854	the	the	B-NP	DT	O	24	NMOD	O
O	O	O	1855	1865	chronicity	chronicity	I-NP	NN	O	22	PMOD	O
O	O	O	1866	1868	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	1869	1872	the	the	B-NP	DT	O	27	NMOD	O
O	O	O	1873	1880	disease	disease	I-NP	NN	O	25	PMOD	O
O	O	O	1880	1881	,	,	O	,	O	18	P	O
O	O	O	1882	1885	and	and	O	CC	O	18	VMOD	O
O	O	O	1886	1889	may	may	B-VP	MD	O	18	VMOD	O
O	O	O	1890	1898	identify	identify	I-VP	VB	O	30	VC	O
O	O	O	1899	1900	a	a	B-NP	DT	O	35	NMOD	O
O	O	O	1901	1906	novel	novel	I-NP	JJ	O	34	AMOD	O
O	O	O	1907	1918	therapeutic	therapeutic	I-NP	JJ	O	35	NMOD	O
O	O	O	1919	1925	target	target	I-NP	NN	O	31	OBJ	O
O	O	O	1926	1928	in	in	B-PP	IN	O	31	VMOD	O
O	O	O	1929	1933	this	this	B-NP	DT	O	39	NMOD	O
O	O	O	1934	1946	inflammatory	inflammatory	I-NP	JJ	O	39	NMOD	O
O	O	O	1947	1959	vasculopathy	vasculopathy	I-NP	NN	O	36	PMOD	O
O	O	O	1959	1960	.	.	O	.	O	18	P	O
